Abstract
Immune adherence assays revealed that 10 out of 18 melanoma patients had demonstrable antibody to surface antigens of autologous cultured melanoma cells, with serum titers ranging from 1/4 to 1/160. Autologous fibroblasts showed no reactions with these sera. Antibody from individual patients showed reproducible temperature preference for maximal reactivity. Two new melanoma antigenic systems were defined in this study. The first, BD, was restricted to autologous melanoma and could not be demonstrated in absorption tests on 12 allogeneic melanoma cell lines. The other, AH, was found on 5 of 12 melanomas and represents a class of shared melanoma surface antigens. Neither BD nor AH antigen was found on normal cells from autologous, allogeneic, or xenogeneic sources or on any nonmelanoma tumor cell line. Methods are now available to develop a comprehensive serological classification of the surface antigens of melanoma.
Full Text
The Full Text of this article is available as a PDF (660.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodurtha A. J., Chee D. O., Laucius J. F., Mastrangelo M. J., Prehn R. T. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 1975 Jan;35(1):189–193. [PubMed] [Google Scholar]
- Boyse E. A., Stockert E., Old L. J. Isoantigens of the H-2 and Tla loci of the mouse: interactions affecting their representation on thymocytes. J Exp Med. 1968 Jul 1;128(1):85–95. doi: 10.1084/jem.128.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cornain S., de Vries J. E., Collard J., Vennegoor C., van Wingerden I., Rümke P. Antibodies and antigen expression in human melanoma detected by the immune adherence test. Int J Cancer. 1975 Dec 15;16(6):981–997. doi: 10.1002/ijc.2910160612. [DOI] [PubMed] [Google Scholar]
- Kodera Y., Bean M. A. Antibody-dependent cell-mediated cytotoxicity for human monolayer target cells bearing blood group and transplantation antigens and for melanoma cells. Int J Cancer. 1975 Oct 15;16(4):579–592. doi: 10.1002/ijc.2910160408. [DOI] [PubMed] [Google Scholar]
- Lewis M. G., Phillips T. M. The specificity of surface membrane immunofluorescence in human malignant melanoma. Int J Cancer. 1972 Jul 15;10(1):105–111. doi: 10.1002/ijc.2910100114. [DOI] [PubMed] [Google Scholar]
- Lewis M. G. Possible immunological factors in human malignant melanoma in Uganda. Lancet. 1967 Oct 28;2(7522):921–922. doi: 10.1016/s0140-6736(67)90236-x. [DOI] [PubMed] [Google Scholar]
- Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
- Nairn R. C., Nind A. P., Guli E. P., Davies D. J., Little J. H., Davis N. C., Whitehead R. H. Anti-tumor immunoreactivity in patients with malignant melanoma. Med J Aust. 1972 Feb 26;1(9):397–403. [PubMed] [Google Scholar]
- Old L. J., Boyse E. A., Stockert E. The G (Gross) leukemia antigen. Cancer Res. 1965 Jul;25(6):813–819. [PubMed] [Google Scholar]
- Romsdahl M. M., Cox I. S. Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch Surg. 1970 Apr;100(4):491–497. doi: 10.1001/archsurg.1970.01340220167028. [DOI] [PubMed] [Google Scholar]
- Tachibana T., Klein E. Detection of cell surface antigens on monolayer cells. I. The application of immune adherence on a micro scale. Immunology. 1970 Nov;19(5):771–782. [PMC free article] [PubMed] [Google Scholar]